Beta-Defensin vs Bronchogen
A side-by-side research comparison of Beta-Defensin and Bronchogen across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Beta-Defensin | Bronchogen |
|---|---|---|
| Full name | Human Beta-Defensin Peptides | Bronchogen (Ala-Asp-Glu-Leu Bronchopulmonary Bioregulator) |
| Category | Immune Support | Immune Support |
| Status | Research compound | Research compound (peptide bioregulator) |
| Mechanism | Form pores in microbial membranes causing lysis, recruit immune cells via CCR6 receptor chemotaxis, and bridge innate and adaptive immunity by activating dendritic cells. | As a signal peptide (Ala-Asp-Glu-Leu), it is proposed to regulate gene expression in respiratory epithelial tissue, supporting airway lining integrity, antioxidant defense, and local respiratory immune function. |
| Molecular weight | 4000-5000 Da | ~445 Da |
| Half-life | ~2-4 hours | Short (peptide) |
| Bioavailability | Primarily local/mucosal activity | Oral (encapsulated) or subcutaneous |
| Typical dose | 50-200 mcg | ~1-2 capsules/day or short injectable courses |
| Frequency | Daily or as needed | Once daily |
| Route | Topical or subcutaneous | Oral capsule or subcutaneous |
Beta-Defensin reported benefits
- Broad antimicrobial activity
- Immune cell recruitment
- Wound healing support
- Biofilm disruption
Bronchogen reported benefits
- Respiratory/airway support
- Bronchopulmonary tissue maintenance (proposed)
- Local respiratory immune support
- Short course-based protocol
Related comparisons
Research and educational reference only. Not medical advice.